Atuzabrutinib

Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling[1].

Product Specifications

CAS Number

[1581714-49-9]

Product Name Alternative

SAR 444727; PRN473

UNSPSC

12352005

Hazard Statement

H315-H319

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/atuzabrutinib.html

Purity

98.01

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=C2C(N([C@H]3CN(CCC3)C(/C(C#N)=C/C(C)(C)C)=O)N=C2C4=C(C=C(C=C4)OC5=CC=CC=C5)F)=NC=N1

Molecular Formula

C30H30FN7O2

Molecular Weight

539.60

Precautions

P264-P280-P302+P352-P305+P351+P338-P362+P364

References & Citations

[1]Herter JM, et al. PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. Br J Pharmacol. 2018;175 (3) :429-439.